Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company advancing targeted therapies in precision oncology and metabolic disorders. This page serves as the definitive source for CRBP news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Access verified information on clinical trial progress, regulatory milestones, and strategic partnerships across CRBP's pipeline. Key focus areas include Nectin-4 targeting antibody-drug conjugates, TGFβ pathway inhibitors, and novel obesity treatments designed to address critical unmet medical needs.
Our curated news collection enables efficient tracking of CRBP's innovative approaches to drug development. Stay informed about emerging data from studies evaluating CRB-701 in solid tumors, CRB-601's impact on tumor microenvironments, and CRB-913's potential in weight management.
Bookmark this page for direct access to official press releases and third-party analyses. Regular updates ensure you maintain current awareness of CRBP's position at the forefront of precision medicine development.
Corbus Pharmaceuticals (NASDAQ: CRBP) has reported Q2 2025 financial results and provided updates on its three clinical programs. The company posted a net loss of $17.7 million ($1.44 per share) and holds $116.6 million in cash, sufficient to fund operations through Q2 2027.
Key developments include: CRB-701 (Nectin-4 targeting ADC) Phase 1/2 dose expansion data to be presented at ESMO 2025, with Fast Track designation for cervical cancer treatment; CRB-913 (obesity drug) has initiated its 7-day MAD study phase with SAD/MAD data expected later this year; and CRB-601 (anti-αvβ8 integrin mAB) is progressing with dose escalation data expected in Q4 2025.
All three clinical programs are on track for data readouts in H2 2025.Corbus Pharmaceuticals (NASDAQ: CRBP) announced the acceptance of their abstract for presentation at the ESMO Congress 2025 in Berlin. The presentation will showcase updated clinical data from their Phase 1/2 study of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate.
The study (NCT06265727) is evaluating CRB-701 in patients with advanced solid tumors expressing Nectin-4. Part A evaluated four doses (1.8-4.5 mg/kg Q3W), with ongoing dose optimization in Part B at 2.7 and 3.6 mg/kg cohorts in HNSCC, cervical, and mUC tumors. The company expects to identify a recommended Phase 2 dose in Q4 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist targeting obesity treatment. This advancement follows the successful completion of the single ascending dose (SAD) study's safety and pharmacokinetics analysis.
The MAD study will evaluate once-daily dosing of CRB-913 for 7 days in healthy volunteers, focusing on safety, tolerability, and pharmacokinetics. Notably, no treatment-related neuropsychiatric events were observed during the SAD portion, even at doses significantly higher than those expected for clinical efficacy.
The company has outlined a clear development timeline: The SAD/MAD portion is scheduled for completion in Q3 2025, followed by a Phase 1b dose-range finding study in obese individuals starting in Q4 2025, with completion expected in the second half of 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the PD-1 combination arm of its Phase 1 study for CRB-701, dosing its first participant. The combination therapy involves CRB-701 with Keytruda® (pembrolizumab) at doses of 2.7 mg/kg and 3.6 mg/kg.
The three-part Phase 1 study (NCT06265727) focuses on advanced solid tumors with high Nectin-4 expression, with over 100 participants dosed in the monotherapy cohort. The study prioritizes Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer. The company plans to provide a data update and establish the recommended Phase 2 dose in Q4 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced its participation in the upcoming Piper Sandler 3rd Annual Virtual Obesity Symposium on June 26, 2025. CEO Yuval Cohen, Ph.D. will engage in a fireside chat at 10:00 a.m. ET, hosted by Biren Amin, Managing Director of Healthcare Equity Research at Piper Sandler.
The symposium will feature presentations from key opinion leaders and fireside chats with companies developing obesity therapeutics. The event is exclusively available to Piper Sandler clients through their representatives.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will deliver a corporate presentation at the upcoming Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4, 2025, at 4:55 p.m. ET. In addition to the presentation, Dr. Cohen will participate in one-on-one meetings with investors during the conference, which runs from June 3-5, 2025. A webcast of the presentation will be available for interested parties.
Corbus Pharmaceuticals (NASDAQ: CRBP) has appointed Rachelle Jacques as Chair of its Board of Directors, effective May 15, succeeding Alan Holmer who will remain on the Board. Jacques, who has served on Corbus' Board for over six years, brings more than 25 years of leadership experience across CEO, commercial, financial, and operational roles. The appointment comes at a crucial time as Corbus anticipates clinical readouts from all three drugs in its pipeline in the second half of 2025, including targeted oncology programs CRB-701 and CRB-601, and an obesity program.
Jacques' extensive experience includes serving as CEO of Akari Therapeutics and Enzyvant Therapeutics, where she achieved FDA approval for RETHYMIC®. She has also held executive positions at Alexion Pharmaceuticals, Baxalta, and Baxter International. Currently, she serves on the board of directors of uniQure N.V. and holds a bachelor's degree in business administration from Alma College.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will participate in the 2025 RBC Capital Markets Global Healthcare Conference. The event will take place in New York from May 20-21, 2025. Dr. Cohen will engage in a fireside chat and one-on-one investor meetings on May 21 at 8:30 a.m. ET. The presentation will be available via webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated dosing in a Phase 1 clinical trial for CRB-913, their second-generation CB1 inverse agonist targeting obesity treatment. The drug represents an advancement over first-generation treatments like rimonabant, which were discontinued due to neuropsychiatric side effects.
Pre-clinical data from Obesity Week 2024 shows CRB-913 is significantly more peripherally restricted, with a brain-to-plasma ratio 50 times lower than rimonabant and 15 times more peripherally restricted than monlunabant. The single ascending dose/multiple ascending dose (SAD/MAD) trial is expected to complete in Q3 2025, followed by a Phase 1b dose-range finding study scheduled for completion in H2 2026.
The company envisions potential applications for CRB-913 as a monotherapy, in combination with incretin analogs, or as maintenance therapy following incretin analog treatment.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
